Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2016-08-24 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to second quarter and first half year 2016 presentation
Report Publication Announcement Classification · 95% confidence The document is very short (918 characters) and explicitly serves as an 'Invitation to second quarter and first half year 2016 presentation'. It announces the time and venue for a presentation covering the Q2 and H1 2016 results, asking recipients to confirm attendance. This structure—announcing an upcoming event where results will be discussed—is characteristic of a Report Publication Announcement (RPA) or an invitation related to an earnings/interim report presentation, rather than the full report (IR) or the earnings release (ER) itself. Since it is an announcement about the presentation of the interim results, RPA is the most fitting category based on the 'MENU VS MEAL' rule, as it is an announcement about the event where the results will be shared.
2016-08-24 English
PCI Biotech: Publication of the fimaporfin (Amphinex) first-in-man Phase I study in Lancet Oncology
Regulatory Filings Classification · 95% confidence The document is a press release dated July 28, 2016, announcing that the results of a Phase I clinical study for their drug fimaporfin (Amphinex) have been published in the medical journal 'Lancet Oncology'. This is not the full financial report (10-K), an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about a specific piece of company news (a publication of clinical trial data). Since it doesn't fit the specific categories like 'Legal Proceedings Report' (LTR) or 'Management Reports' (MDA), and it is a general regulatory/news announcement, the most appropriate general category is 'Regulatory Filings' (RNS), which serves as a fallback for significant, non-standard announcements not covered elsewhere, or potentially 'Report Publication Announcement' (RPA) if we strictly interpret 'publication' as the key action. However, RNS is better suited for general news releases about clinical trial outcomes being published, especially when the document itself is the announcement, not the published paper. Given the context of a company announcing a publication, RNS is the best fit among the available options for a general news disclosure.
2016-07-28 English
PCI Biotech receives positive opinion for Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU
Environmental & Social Information Classification · 99% confidence The document announces a specific corporate event: PCI Biotech receiving a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) regarding Orphan Drug Designation for fimaporfin. This is a material development concerning the company's pipeline and regulatory status, but it does not fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions like dividends (DIV) or capital changes (CAP/SHA). It is a regulatory/pipeline update that is not explicitly covered by other codes like LTR (Legal Proceedings) or AR (Audit Report). Given the nature of the announcement—a specific, material regulatory development that doesn't fit the defined categories for financial results, management changes, or shareholder meetings—the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements.
2016-07-25 English
PCI Biotech: Pre-clinical research collaboration agreement with top-10 large pharma company extended
Regulatory Filings Classification · 100% confidence The document announces the extension of a pre-clinical research collaboration agreement between PCI Biotech and an undisclosed large pharma company regarding technology evaluation. This announcement details a business development activity, specifically related to ongoing research and potential future partnerships, rather than a mandatory financial filing (like 10-K, ER, IR) or a specific corporate action announcement (like DIV, SHA, DIRS). Since it is a specific business development update that doesn't fit the primary financial or governance categories, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard announcements, or potentially 'LTR' if it were a legal proceeding, but here it is a commercial agreement update. Given the options, RNS is the most appropriate general regulatory/business announcement category for this type of news release that isn't a core financial report or governance document.
2016-05-26 English
PCI Biotech: Minutes from Annual General Meeting 2016
AGM Information Classification · 100% confidence The document text is titled 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING' which translates to 'MINUTES FROM ORDINARY GENERAL MEETING'. The content details the proceedings, resolutions passed (like approving the annual accounts and annual report for 2015), and the structure of a formal meeting held on May 19, 2016. This clearly identifies the document as the official record or minutes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2016-05-19 English
PCI Biotech: Minutes from Annual General Meeting 2016
AGM Information Classification · 99% confidence The document explicitly states it contains the "Minutes from Annual General Meeting 2016" and details the election of a new Board of Directors during the AGM. Although it mentions the minutes are attached, the primary content is the summary of the AGM proceedings and outcomes (board election). This strongly aligns with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. It is not just an announcement of a report, but the summary/minutes themselves.
2016-05-19 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.